Stocks· August 20, 2026 at 10:07 PM

JPMorgan sees 100% upside in overlooked cancer drug stock

Authored by·Editorially reviewed

Founder, Financial Engineer · CMB-licensed

Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.

NeutralMedium impact

AI summary

The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.

Affected symbols

JPM

Yahoo Finance · Read original

AI commentary is generated from public news feeds and is not investment advice.

Related coverage

StocksMedium impactNeutral1h

Questor Technology Signs Letter of Intent to Acquire Emission Rx in Strategic Move to Lead North American Emissions Combustion Technology

via GlobalNewswire

StocksMedium impactNeutral1h

Wall Street sinks as bond yields rise, Walmart results disappoint - Reuters

via Reuters

StocksMedium impactNeutral1h

Asian Stocks Set to Fall as Bonds Resume Decline: Markets Wrap - Bloomberg

via Bloomberg

StocksMedium impactNeutral1h

Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead

via Yahoo Finance

NVDA